A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
- 25 May 2011
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 3 (84), 84ra43
- https://doi.org/10.1126/scitranslmed.3002254
Abstract
Reducing production of amyloid-β (Aβ) peptide by direct inhibition of the enzymes that process amyloid precursor protein (APP) is a central therapeutic strategy for treating Alzheimer’s disease. However, small-molecule inhibitors of the β-secretase (BACE1) and γ-secretase APP processing enzymes have shown a lack of target selectivity and poor penetrance of the blood-brain barrier (BBB). Here, we have developed a high-affinity, phage-derived human antibody that targets BACE1 (anti-BACE1) and is anti-amyloidogenic. Anti-BACE1 reduces endogenous BACE1 activity and Aβ production in human cell lines expressing APP and in cultured primary neurons. Anti-BACE1 is highly selective and does not inhibit the related enzymes BACE2 or cathepsin D. Competitive binding assays and x-ray crystallography indicate that anti-BACE1 binds noncompetitively to an exosite on BACE1 and not to the catalytic site. Systemic dosing of mice and nonhuman primates with anti-BACE1 resulted in sustained reductions in peripheral Aβ peptide concentrations. Anti-BACE1 also reduces central nervous system Aβ concentrations in mouse and monkey, consistent with a measurable uptake of antibody across the BBB. Thus, BACE1 can be targeted in a highly selective manner through passive immunization with anti-BACE1, providing a potential approach for treating Alzheimer’s disease. Nevertheless, therapeutic success with anti-BACE1 will depend on improving antibody uptake into the brain.Keywords
This publication has 31 references indexed in Scilit:
- What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?Biological Psychiatry, 2010
- Can Alzheimer disease be prevented by amyloid-β immunotherapy?Nature Reviews Neurology, 2010
- Amyloid Precursor Protein Trafficking, Processing, and FunctionPublished by Elsevier BV ,2008
- β-Secretase as a Therapeutic Target for Alzheimer's DiseaseNeurotherapeutics, 2008
- Immunotherapy for Alzheimer's disease: attacking amyloid-β from the insideTrends in Immunology, 2007
- Phenotypic and Biochemical Analyses of BACE1- and BACE2-deficient MicePublished by Elsevier BV ,2005
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeuticsHuman Molecular Genetics, 2001
- Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generationNature Neuroscience, 2001
- BACE1 is the major β-secretase for generation of Aβ peptides by neuronsNature Neuroscience, 2001